Hansa Biopharma AB launches new name and unveils logo
Søren Tulstrup, CEO of Hansa Biopharma, comments: “Our new name, Hansa Biopharma, represents the next stage in the Company’s lifecycle and emphasizes our focus on the development and commercialization of biopharmaceuticals. The Hansa Biopharma logo expresses optimism and inspiration. Its dynamic form reflects the idea of a ‘hansa’ as a group of skilled individuals combining for a greater purpose, shining outward to represent the benefits we aim to deliver via our enzymology platform to people affected by a rare immunopathology.”
The corporate website, at the new address of www.hansabiopharma.com, will fully reflect the new identity over the coming weeks.
This change follows the approval, by the Bolagsverket in Sweden, of resolutions approved at an Extraordinary General Meeting ("EGM") held on December 4, 2018.
The information was submitted for publication, through the agency of the contact person set out below, at 8:00 am CET on February 1, 2019.
For further information, please contact:
Emanuel Björne, Vice President Business Development and Investor Relations, Hansa Biopharma AB (publ)
Mobile: +46 707 175477
Swedish Investor and Media Relations:
+46 70-311 99 60
U.K. Investor and Media Relations
Simon Conway/ Stephanie Cuthbert
+44 (0)20 3727 1000
U.S. Investor and Media Relations:
Stephanie Marks / David Rosen (media)
+1 212 600 1902